The BUTTERFLEYE trial sought to determine if aflibercept, an anti–vascular endothelial growth factor (anti-VEGF) therapy, was equivalent to laser photocoagulation, the gold standard to treat ...

SAN FRANCISCO — Retinopathy of prematurity seems to respond equally to either an injection with aflibercept or laser photocoagulation when infants who were treated reached age 2 years, according to ...

A race to find the best treatment for premature babies at risk for retinopathy of prematurity (ROP) the leading cause of childhood vision loss and blindness has spurred both controversy and research.

Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, R.V. Paul Chan, MD, discusses treatment ...

Newly published research details a different approach to treating premature infants at risk for retinopathy of prematurity (ROP)—the leading cause of childhood vision loss and blindness. In normally ...

Please provide your email address to receive an email when new articles are posted on . “The BEAT-ROP study demonstrated a beneficial effect for bevacizumab vs. laser in the treatment of zone I, stage ...

BUFFALO, N.Y. – A University at Buffalo researcher who is a leading expert on retinopathy of prematurity (ROP) has published a study that could change the standard of care for the condition. ROP ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Retinopathy of prematurity (ROP) that occurs in preterm babies can progress fast, which requires quick decisions early about treatment, explained Darius M. Moshfeghi, MD, chief, Retina Division, and ...